Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRIX |
---|---|---|
09:32 ET | 7900 | 25.4 |
09:34 ET | 3700 | 25.85 |
09:36 ET | 1900 | 25.545 |
09:38 ET | 1092 | 25.25 |
09:39 ET | 100 | 25.34 |
09:41 ET | 500 | 25.25 |
09:43 ET | 700 | 25.33 |
09:45 ET | 100 | 25.325 |
09:48 ET | 2400 | 25.59 |
09:50 ET | 1100 | 25.225 |
09:52 ET | 200 | 25.09 |
09:54 ET | 1525 | 25.03 |
09:56 ET | 1100 | 25.14 |
09:57 ET | 200 | 25.14 |
09:59 ET | 200 | 25.055 |
10:01 ET | 4698 | 25.24 |
10:03 ET | 10755 | 25.4 |
10:06 ET | 400 | 25.32 |
10:08 ET | 200 | 25.5 |
10:10 ET | 300 | 25.48 |
10:12 ET | 900 | 25.49 |
10:14 ET | 3600 | 25.55 |
10:15 ET | 1200 | 25.52 |
10:17 ET | 100 | 25.46 |
10:19 ET | 1345 | 25.425 |
10:21 ET | 1900 | 25.63 |
10:24 ET | 2065 | 25.44 |
10:26 ET | 300 | 25.43 |
10:28 ET | 2430 | 25.365 |
10:30 ET | 1100 | 25.59 |
10:32 ET | 100 | 25.44 |
10:33 ET | 205 | 25.56 |
10:35 ET | 3604 | 25.65 |
10:37 ET | 2275 | 25.56 |
10:39 ET | 2288 | 25.635 |
10:42 ET | 1811 | 25.68 |
10:44 ET | 800 | 25.56 |
10:46 ET | 400 | 25.61 |
10:48 ET | 1400 | 25.53 |
10:50 ET | 300 | 25.5 |
10:51 ET | 460 | 25.5 |
10:53 ET | 200 | 25.47 |
10:55 ET | 5077 | 25.51 |
10:57 ET | 100 | 25.535 |
11:00 ET | 1632 | 25.46 |
11:02 ET | 2899 | 25.56 |
11:04 ET | 700 | 25.56 |
11:06 ET | 4351 | 25.63 |
11:08 ET | 427 | 25.53 |
11:09 ET | 1000 | 25.575 |
11:11 ET | 100 | 25.63 |
11:13 ET | 3764 | 25.75 |
11:15 ET | 300 | 25.75 |
11:18 ET | 500 | 25.7 |
11:20 ET | 300 | 25.69 |
11:22 ET | 4895 | 25.8 |
11:24 ET | 900 | 25.8 |
11:26 ET | 200 | 25.8 |
11:27 ET | 1258 | 25.85 |
11:29 ET | 1200 | 25.85 |
11:31 ET | 4177 | 25.895 |
11:36 ET | 1649 | 25.92 |
11:38 ET | 5990 | 25.85 |
11:40 ET | 100 | 25.82 |
11:42 ET | 200 | 25.82 |
11:44 ET | 900 | 25.85 |
11:45 ET | 2697 | 25.83 |
11:47 ET | 1673 | 25.78 |
11:49 ET | 1350 | 25.69 |
11:54 ET | 920 | 25.705 |
11:56 ET | 2078 | 25.8 |
11:58 ET | 700 | 25.76 |
12:00 ET | 200 | 25.76 |
12:02 ET | 2648 | 25.6 |
12:03 ET | 400 | 25.65 |
12:05 ET | 400 | 25.69 |
12:07 ET | 300 | 25.65 |
12:09 ET | 1100 | 25.755 |
12:12 ET | 904 | 25.8 |
12:14 ET | 500 | 25.76 |
12:18 ET | 700 | 25.75 |
12:20 ET | 500 | 25.8 |
12:21 ET | 1205 | 25.79 |
12:23 ET | 3089 | 25.825 |
12:25 ET | 5325 | 25.825 |
12:27 ET | 500 | 25.825 |
12:30 ET | 828 | 25.78 |
12:32 ET | 500 | 25.795 |
12:34 ET | 500 | 25.78 |
12:36 ET | 1970 | 25.685 |
12:38 ET | 1246 | 25.675 |
12:39 ET | 603 | 25.7 |
12:41 ET | 1276 | 25.675 |
12:43 ET | 200 | 25.6775 |
12:45 ET | 693 | 25.675 |
12:48 ET | 1008 | 25.68 |
12:50 ET | 400 | 25.68 |
12:52 ET | 2400 | 25.81 |
12:54 ET | 1206 | 25.795 |
12:56 ET | 600 | 25.8 |
12:57 ET | 1091 | 25.77 |
12:59 ET | 2135 | 25.725 |
01:01 ET | 1236 | 25.79 |
01:03 ET | 900 | 25.785 |
01:06 ET | 668 | 25.76 |
01:08 ET | 100 | 25.78 |
01:10 ET | 300 | 25.7 |
01:12 ET | 400 | 25.74 |
01:14 ET | 300 | 25.7 |
01:15 ET | 500 | 25.74 |
01:17 ET | 200 | 25.735 |
01:19 ET | 400 | 25.75 |
01:21 ET | 1328 | 25.77 |
01:24 ET | 6881 | 25.77 |
01:26 ET | 1400 | 25.77 |
01:28 ET | 527 | 25.75 |
01:30 ET | 400 | 25.72 |
01:32 ET | 300 | 25.7 |
01:33 ET | 500 | 25.68 |
01:35 ET | 1000 | 25.615 |
01:37 ET | 505 | 25.6 |
01:39 ET | 800 | 25.61 |
01:42 ET | 550 | 25.605 |
01:44 ET | 500 | 25.56 |
01:46 ET | 1000 | 25.575 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nurix Therapeutics Inc | 1.6B | -8.8x | --- |
Arvinas Inc | 1.7B | -4.9x | --- |
Immatics NV | 1.3B | -13.1x | --- |
Arcus Biosciences Inc | 1.5B | -5.5x | --- |
Bicycle Therapeutics PLC | 1.7B | -6.7x | --- |
Arcutis Biotherapeutics Inc | 1.2B | -4.7x | --- |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
---|---|
Revenue (TTM) | $62.3M |
Shares Outstanding | 64.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $-2.92 |
Book Value | $4.12 |
P/E Ratio | -8.8x |
Price/Sales (TTM) | 25.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -287.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.